Quick Answer
HALOZYME THERAPEUTICS, INC. reported Operating Income Loss of $469.01 million for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -15.0% in Operating Income Loss from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$12.15 million | Q3 2010: -$12.43 million | Q1 2011: -$9.66 million | Q2 2011: $3.10 million | Q3 2011: $5.15 million | Q1 2012: -$15.14 million | Q2 2012: -$14.05 million | Q3 2012: -$20.03 million | Q1 2013: -$18.50 million | Q2 2013: -$22.12 million | Q3 2013: -$18.49 million | Q1 2014: -$25.22 million | Q2 2014: -$14.94 million | Q3 2014: -$19.03 million | Q1 2015: -$13.91 million | Q2 2015: $4.23 million | Q3 2015: -$23.24 million | Q1 2016: -$16.17 million | Q2 2016: -$21.72 million | Q3 2016: -$22.74 million | Q1 2017: -$27.53 million | Q2 2017: -$25.48 million | Q3 2017: $8.08 million | Q1 2018: -$23.71 million | Q2 2018: -$20.07 million | Q3 2018: -$25.47 million | Q1 2019: $2.97 million | Q2 2019: -$13.98 million | Q3 2019: -$24.54 million | Q1 2020: -$3.22 million | Q2 2020: $29.56 million | Q3 2020: $40.30 million | Q1 2021: $50.74 million | Q2 2021: $93.05 million | Q3 2021: $75.59 million | Q1 2022: $75.67 million | Q2 2022: $34.06 million | Q3 2022: $83.29 million | Q1 2023: $53.80 million | Q2 2023: $94.46 million | Q3 2023: $88.28 million | Q1 2024: $95.54 million | Q2 2024: $117.24 million | Q3 2024: $163.20 million | Q1 2025: $141.54 million | Q2 2025: $202.44 million | Q3 2025: $217.92 million.
- Over the full 17 years of available data (2009 to 2025), HALOZYME THERAPEUTICS, INC.'s Operating Income Loss has grown by 902.3%.
- Historical annual values: Fiscal year 2025: $469.01 million | Fiscal year 2024: $551.48 million | Fiscal year 2023: $337.57 million | Fiscal year 2022: $267.53 million | Fiscal year 2021: $275.90 million | Fiscal year 2020: $144.26 million | Fiscal year 2019: -$67.61 million | Fiscal year 2018: -$69.33 million | Fiscal year 2017: $81.00 million | Fiscal year 2016: -$83.21 million | Fiscal year 2015: -$27.45 million | Fiscal year 2014: -$63.04 million | Fiscal year 2013: -$80.43 million | Fiscal year 2012: -$53.63 million | Fiscal year 2011: -$19.84 million | Fiscal year 2010: -$54.26 million | Fiscal year 2009: -$58.46 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: